Vivozon Inc.
Vivozon - Model VVZ-149 - Opiranserin
FromVivozon Inc.
Opiranserin (VVZ-149) for injection is a first-in-class non-narcotic analgesic under development by Vivozon. As atreatment for postoperative pain used as a first-line therapy in the global market, Opiranserin aims to ultimately replaceopioid analgesics by providing an effective and safe solution for pain management. With the hope to combat opioidmisuse and abuse, Opiranserin is currently undergoing phase 3 clinical trials in Korea and the United States.
Most popular related searches
narcotics analgesic
central nervous system
anti-inflammatory drug
pain management system
postoperative pain
opioid use
nervous system
pain management
analgesic use
inflammatory drug
- Among the non-narcotic analgesics under development, it ranks among the top in terms of efficacy, safety, and development stages.
- Anticipated analgesic efficacy comparable or superior to that of opioids
- Excellent safety: Overcoming the side effects of opioid analgesics and anti-inflammatory drugs
- Rapid postoperative pain management, systemic administration, analgesic efficacy in opioid-tolerant patients
- It is a multi-target new drug that simultaneously acts on GlyT2 and 5HT2a, which are involved in the generation, transmission, and regulation of pain signals. It exerts analgesic effects upon both the central nervous system and the peripheral nervous system.
- In particular, it has a synergistic effect of analgesic efficacy by simultaneously inhibiting two targets in the spinal cord, which is a key area that regulates pain signals going up to the brain.
Primary objective
- Reduction of opioid use through the analgesic effect of Opiranserin
- Confirmed opioid reduction of at least 30-50%
Ultimate goal
- Replacement of narcotic analgesic use after surgery and opioid use during surgery
- Expected to be used as a first-in-line treatment for pain before and after surgery